Microbot Medical Strengthens Global IP Portfolio with Newly Granted Patent in China

Core Insights - Microbot Medical Inc. has been granted a critical patent in China for its LIBERTY Endovascular Robotic System, marking a significant step in its global intellectual property expansion strategy [1] - The company currently holds nine patents globally and has 59 pending patent applications, which helps maintain a competitive advantage and protect the unique capabilities of the LIBERTY System [2] - Preparations for the anticipated U.S. launch of the LIBERTY System are underway, with regulatory, operational, and commercial activities accelerating [3] - The company aims to impact both developed and emerging markets, with an estimated 2 million peripheral endovascular procedures performed annually in the U.S. and approximately 2.9 million in China [4] - Microbot Medical is focused on redefining endovascular robotics and improving patient care through its innovative, single-use, fully disposable robotic system [5]